Many therapeutic protein drugs are perceived by the body as foreign entities and are hence targeted for attack and clearance by the immune system, thus rendering treatment ineffective and potentially dangerous. Anokions platform immune tolerance technology harnesses the power of natural immune regulation by engineering therapeutic proteins to be perceived as self entities, thereby offering a means to reduce immunogenicity of existing therapeutics and further enable clinical translation of proteins previously thought to be too immunogenic for repeated use.
Patients suffering from autoimmune diseases harbor immune cells that erroneously recognize naturally occurring self-proteins as foreign, causing tissue destruction and inflammation. The current therapeutic modality for treating such
07.10.2024
FDA approvals and clinical advancements propel life sciences startups forward (startupticker.ch)
21.10.2022
Pfizer invests $35 million in Anokion (startupticker.ch)
24.03.2021
Anokion advances second drug candidate into clinical trials (startupticker.ch)
26.02.2021
Female leaders at the top (startupticker.ch)
22.01.2020
Anokion receives FDA Clearance (startupticker.ch)
No milestones
No Jobs
No videos and documents
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Website:
anokion.com/
Headquarter:
Ecublens
Foundation Date:
March 2010
Technology: